Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Sep 05, 2024

SELL
$34.88 - $43.22 $88,595 - $109,778
-2,540 Closed
0 $0
Q4 2022

Sep 05, 2024

BUY
$33.8 - $47.06 $85,852 - $119,532
2,540 New
2,540 $118 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $15.2B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Granite Fo LLC Portfolio

Follow Granite Fo LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granite Fo LLC, based on Form 13F filings with the SEC.

News

Stay updated on Granite Fo LLC with notifications on news.